Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $21.14

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $21.14.

A number of brokerages have recently weighed in on YMAB. Canaccord Genuity Group reissued a “buy” rating and set a $26.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Morgan Stanley reduced their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a report on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of Y-mAbs Therapeutics in a report on Monday. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Finally, Truist Financial started coverage on Y-mAbs Therapeutics in a research report on Friday, June 28th. They issued a “buy” rating and a $21.00 price objective for the company.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the sale, the chief operating officer now owns 30,600 shares in the company, valued at approximately $449,514. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 21.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Campbell & CO Investment Adviser LLC bought a new position in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $562,000. China Universal Asset Management Co. Ltd. grew its stake in Y-mAbs Therapeutics by 66.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 8,390 shares of the company’s stock valued at $136,000 after purchasing an additional 3,340 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in Y-mAbs Therapeutics by 39.9% in the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after purchasing an additional 1,056 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Y-mAbs Therapeutics by 8.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after purchasing an additional 1,657 shares during the last quarter. Finally, Caxton Associates LP bought a new stake in shares of Y-mAbs Therapeutics during the 1st quarter worth approximately $306,000. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ YMAB opened at $13.37 on Friday. Y-mAbs Therapeutics has a fifty-two week low of $4.69 and a fifty-two week high of $20.90. The firm has a market capitalization of $586.72 million, a P/E ratio of -27.29 and a beta of 0.70. The company’s 50 day simple moving average is $12.50 and its 200 day simple moving average is $13.63.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). The company had revenue of $22.80 million during the quarter, compared to analyst estimates of $23.09 million. Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. During the same period last year, the company earned ($0.14) EPS. Sell-side analysts expect that Y-mAbs Therapeutics will post -0.57 EPS for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.